WaveMan
WaveMan · Company
EXOZ · Exozymes Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

EXOZ Exozymes (EXOZ) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0002010788
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
7
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · no price filed

What the filings say about EXOZ

Insiders, 180 days
-$13.0K net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan

Exozymes insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, EXOZYMES INC. insiders sold a net $13.0K of stock across 9 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Perriman Damien Alan
Chief Commercial Officer
SELL
2026-10-26 SECtraded 2026-10-12
3,729
$19.4K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 13.0% of the 28,692 shares held after it.
  • No other insider sold within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Perriman Damien Alan sold about $19.4K of EXOZ on Oct 12, 2026, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.
Heltzen Michael
Chief Executive Officer
BUY
2026-09-02 SECtraded 2026-08-26
4
$30
-44.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 25, 2026.
  • The trade is 0.0% of the 14,708 shares held after it.
  • No other insider bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Heltzen Michael bought about $30 of EXOZ on Aug 26, 2026; 7 funds added in the latest 13F quarter.
Heltzen Michael
Chief Executive Officer
BUY
2026-09-02 SECtraded 2026-08-26
251
$1.8K
-44.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 25, 2026.
  • The trade is 1.7% of the 14,704 shares held after it.
  • No other insider bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Heltzen Michael bought about $1.8K of EXOZ on Aug 26, 2026; 7 funds added in the latest 13F quarter.
Heltzen Michael
Chief Executive Officer
BUY
2026-09-02 SECtraded 2026-08-26
250
$1.9K
-44.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 25, 2026.
  • The trade is 1.7% of the 14,453 shares held after it.
  • No other insider bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Heltzen Michael bought about $1.9K of EXOZ on Aug 26, 2026, the largest insider purchase at the company since 2025; 7 funds added in the latest 13F quarter.
Heltzen Michael
Chief Executive Officer
BUY
2026-09-02 SECtraded 2026-08-25
250
$1.9K
-44.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 2, 2025.
  • The trade is 1.8% of the 14,203 shares held after it.
  • No other insider bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Heltzen Michael bought about $1.9K of EXOZ on Aug 25, 2026, the largest insider purchase at the company since 2025; 7 funds added in the latest 13F quarter.
9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 4 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$13.0K over 180 days
-$13.0K over 90 days
more than 60% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
7 funds bought in last quarter
below 91% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-27) · 1.9 days to cover · settled 2026-10-15
below 86% of Pharma & Biotech
What changed in the last 30 days
Oct 26Chief Commercial Officer Perriman Damien Alan sold $19.4K (Oct 12)

Watch EXOZ

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-68.8%12M
-69%-33%+2%+38%2025-102025-122026-022026-042026-062026-082026-10 2026-10-12 · Perriman Damien Alan sold $19.4K2026-04-09 · Korman Tyler Paz sold $7.9K2026-04-08 · Korman Tyler Paz sold $7.5K2026-08-26 · Heltzen Michael bought $1.9K2026-08-25 · Heltzen Michael bought $1.9K2026-08-26 · Heltzen Michael bought $1.8K2026-08-25 · Heltzen Michael bought $7502026-08-26 · Heltzen Michael bought $30
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns EXOZ: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
54,985 sh
$463.5K
Davidson Kahn Capital Management, LLC
25,000 sh
$210.8K
GEODE CAPITAL MANAGEMENT, LLC
23,406 sh
$197.3K
BlackRock, Inc.
9,610 sh
$81.0K
VANGUARD FIDUCIARY TRUST CO
9,426 sh
$79.5K

Congress trades in EXOZ

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

EXOZ planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

EXOZ mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$77.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$3.7K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$100.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$188.3K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$19.5K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$28.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $13.0K sold by insiders over 180 days, 7 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

EXOZ financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$7.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-187.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-115.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-142.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-20.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenuen/an/a$70.1K
Operating income-$9.7M-$5.9M-$1.8M
Net income-$9.2M-$5.9M-$2.0M
EPS (diluted)-1.09-0.89-0.33
Operating cash flow-$6.5M-$8.5M-$1.2M
Cash$3.0M$9.7M$66.5K
SEC XBRL, fiscal years, as known on 2026-10-28

EXOZ Stock Sonar score 4/7 axes

Find similar shapesCompare

EXOZ ranks highest on risk and compliance (80th percentile) and insider conviction (57th), and lowest on institutional and government (9th), among Pharma & Biotech peers.

Profitability
18
Inputs
  • Return on equity-187.2% · 18 pct, sector of 545
  • Return on assets-115.4% · 21 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-142.4% · 17 pct, sector of 576
Insider conviction
57
Inputs
  • Net Form 4 buying (codes P and S), 180d-$13K · 59 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
9
Inputs
  • Funds adding, latest quarter7 · 9 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
80
Inputs
  • Short interest, % of float+0.2% · 89 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.1% · 70 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

EXOZ filings, in plain words

Are Exozymes insiders buying or selling EXOZ?

In the 180 days to 2026-10-28, Exozymes insiders were net sellers, a net $13.0K: $6.4K of purchases and $19.4K of sales reported on Form 4, by 1 buyer and 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Exozymes insiders were net sellers of EXOZ, a net $13.0K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies